InDex Pharmaceuticals: CONCLUDE discontinued - Redeye

Redeye leaves its initial comments in response to InDex Pharmaceuticals' announcement regarding the discontinuation of the Phase III program CONCLUDE, which introduces uncertainty regarding the company's future. We anticipate a significant decline in the share today as cobitolimod was the primary value driver in the company; nevertheless, we believe that the cash position (SEK 412.5m at the end of Q2) will help mitigate the impact.

Länk till analysen i sin helhet: https://www.redeye.se/research/962105/index-pharmaceuticals-conclude-discontinued?utm_source=finwire&utm_medium=RSS